Gastroesophageal cancer
Clinical trials for Gastroesophageal cancer explained in plain language.
Never miss a new study
Get alerted when new Gastroesophageal cancer trials appear
Sign up with your email to follow new studies for Gastroesophageal cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
Disease control Not yet recruitingResearchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
Disease control Not yet recruitingThis study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…
Matched conditions: GASTROESOPHAGEAL CANCER
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Not yet recruitingThis phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug duo aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis early-phase trial tests whether adding two targeted drugs (zanidatamab and tislelizumab) to standard chemotherapy can completely eliminate HER2-positive gastroesophageal cancer before surgery. About 29 adults with operable, locally advanced disease will receive the combinati…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase 1/2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC